EDCTP

08:30-10:45

Plenary session III:

Recent advances in HIV/AIDS, malaria and tuberculosis (Keynote Addresses)

Chairs:            Prof. Peter Ndumbe and Prof. Olle Stendahl

08:30-09:10     HIV/AIDS 
                       Dr Anatoli Kamali
  
09:10-09:50     Malaria  
                       Dr Abdoulaye Djimde
  
09:50-10:30     Tuberculosis  
                       Associate Prof. Willem Hanekom
  

10:30-11:00    Coffee/Tea Break

11:00-12:05

Parallel sessions: Clinical Trials in sub-Saharan Africa: Research findings
(Presentations and discussion)

HIV/AIDS  
Chairs             Dr Simon Agwale and Prof. Eric Sandstorm
11:00-11:05      Brief introduction from the Chairs
11:05-11:20      Said Aboud: Safety and immunogenicity of a multigene multiclade Hiv-1 DNA plasmid vaccine boosted with 
                        heterologous HIV mva among healthy volunteers in Dar Es Salaam, Tanzania
11:20-11:35      Joel Francis: Safety Profile Of A Multigene, Multiclade HIV-1 DNA Plasmid Vaccine Boosted With HIV-1 MVA 
                        Among Healthy Volunteers In Dar Es Salaam, Tanzania
11:35-11:50      Max Rosario: Heterologous vaccination regimen using recombinant BCG, ovine atadenovirus and modified 
                        vaccinia virus Ankara induces potent HIV-specific T cell responses in macaques
11:50-12:05      Elise Arrivé: Tolerance and viral dynamics after short-course of nevirapine, tenofovir disoproxil fumarate and 
                        emtricitabine (TDF/FTC) to delivering women and neonates

Malaria      
Chairs              Prof. Alioune Dieye and Prof. Peter Kremsner
11:00-11:05      Brief introduction from the Chairs
11:05-11:20      Umberto D'Alessandro: Artemisinin-based combinations for treating uncomplicated malaria in African 
                        children: The 4abc trial, preliminary results
11:20-11:35      Badara Cisse: A randomized trial of the efficacy and safety of piperaquine in combination with dihydro-
                        artemisinin or sulphadoxine-pyrimethamine for seasonal intermittent preventive treatment (IPT) in Senegalese
                        children
11:35-11:50      Patrice Piola: Efficacy and safety of quinine versus artemether-lumefantrine in uncomplicated malaria during
                        pregnancy, Mbarara, Uganda
11:50-12:05      Kamija Phiri: Intermittent preventive therapy post-discharge (IPTpd); An innovative  approach in the
                        prevention of rebound severe malaria anaemia and mortality in young children

 

Tuberculosis 
Chairs              Prof. Tumani Corrah, Prof. Joseph Odhiambo and Dr Hulda Swai
11:00-11:05       Brief introduction from the Chairs
11:05-11:30       Andrew Nunn: An international multicentre controlled clinical trial to evaluate high dose rifapentine and a 
                         quinolone in the treatment of pulmonary tuberculosis (Rifaquin)
11:30-11:50       Anthony Hawkridge: Partnering to support research capacity in tuberculosis endemic countries
11:50-12:05       Mugahid Elhassan: Similarity between pulmonary tuberculosis and pulmonary nocardiosis; (A bacteriological 
                         and proteomic study)

 
12:05-13:05     Electronic and paper poster presentations

13:00-14:00     Lunch

14:00-16:00 

Parallel sessions: Clinical Trials in sub-Saharan Africa: Research findings (continued)

The 50 minutes discussion at the end of each parallel session should focus on potential important research agenda for each disease area

HIV/AIDS  
Chairs                Prof. Omu Anzala and Dr Rosemary Musonda
14:00-14:05         Brief introduction from the Chairs
14:05-14:20         Veronica Mulenga: Strategies for Nevirapine initiation in HIV-infected children taking  paediatric fixed-dose 
                           combination ‘baby pills’ in Zambia: A randomised controlled trial
14:20-14:35         Mirjam Oudijk: Pharmacokinetics of nevirapine in young children during combined ART and rifampicin-
                           containing antituberculosis treatment
14:35-14:50         Omar JM Hamza: Single-dose fluconazole versus standard two weeks therapy for oropharyngeal candidiasis 
                            in HIV-infected patients: A randomized, double-blind placebo controlled trial
14:50-15:05          Julius Atashili: High prevalence of cervical squamous intraepithelial lesions in women on antiretroviral 
                            therapy in Cameroon: Is targeted screening feasible?
15:10-16:00          Discussion on possible new research questions for HIV and AIDS

Malaria      
Chairs                 Dr Christine Manyando and Dr Saadou Issifou
14:00-14:05          Brief introduction from the Chairs
14:05-14:20          Michael Theisen: Malaria vaccine GMZ2 pre-clinical selection and clinical development
14:20-14:35          Saadou Issifou: Phase Ib randomized controlled double blind trial to evaluate the safety & immunogenicity 
                            of 30 and 100 µg GMZ2 candidate malaria vaccine in Gabonese children aged 1-5 Years
14:35-14:50          Kalifa Bojang: Baseline epidemiological study in preparation for a phase IIb proof of concept efficacy study
                            of GMZ2 candidate malaria vaccine in children aged 12 – 84 months old.
14:50-15:05          Sodiomon Sirima: Facing the challenge of building malaria clinical trials site in developing country: 
                             Achievements and lessons from the Balonghin Malaria Vaccine Trial Centre in Burkina Faso
15:05-15:20          Peter Kremsner/Saadou Issifou: A phase II randomized, double-blind study to compare the efficacy, 
                            safety, tolerability, and pharmacokinetics of two regimens using intravenous artesuate.

15:20-16:00          Discussion on possible new research questions for malaria

Tuberculosis 
Chairs                 Prof. Mecky Matee and Prof. Martin Grobusch

14:00-14:05          Brief introduction from the Chairs
14:05-14:20          Videlis Nduba: The prevalence of tuberculosis infection and disease among adolescents in western Kenya:
                            preparation for future TB vaccine trials.
14:20-14:35          Peter Nyamthimba Onyango: A mobile field site as a model for enrolment and follow up in a tuberculosis 
                            incidence cohort in adolescents, western Kenya, in preparation for future vaccine trials
14:35-14:50          Charles Mtabho: The magnitude of childhood tuberculosis in Kilimanjaro region, northern Tanzania; A 
                            retrospective study from regional tuberculosis program registry
14:50-15:05          Grace Kiringa: A prospective cohort study to evaluate incidence of tuberculosis in infants, western Kenya
15:10-16:00          Discussion on possible new research questions for tuberculosis

16:00-16:30         Coffee/Tea Break

16:30-17:30 

Plenary session IV: Summaries and recommendations for future strategies for conducting HIV/AIDS, malaria and tuberculosis clinical trials in sub-Saharan Africa

Chairs                  Prof. Juhani Eskola and Dr Carolyn Peterson

16:30-17:00           Report back in plenary session focusing on ideas for future research agenda

HIV/AIDS (10 mins):        Dr Shabbar Jaffar and Prof. Walter Jaoko
Malaria (10 mins):            Prof. Peter Kremsner and Dr Christine Manyando
Tuberculosis (10 mins):     Prof. Richard Adegbola, Prof. Mecky Matee and Dr Hulda Swai

17:00-17:30                   Discussion

19:00-20:30                   Cultural Dinner